Regentis Biomaterials
RGNT · NYSE
$1.28−$0.12 (−8.57%)TodayMarket closed ·
Prev close $1.40
Who owns RGNT
No institutional holdings are reported for Regentis Biomaterials.
Insider trades
Form 4 filings by officers, directors and large holders
Insiders made no open-market buys or sales of RGNT in the last 6 months.
| Insider | Type | Shares | Value |
|---|---|---|---|
| Ben-Elazar Pini | Award | 8.31K | — |
| Ben-Elazar Pini | Award | 24.83K | — |
| Cohen-Arazi Efraim | Award | 24.83K | — |
| Dykan Jeff | Award | 24.83K | — |
| Dykan Jeff | Award | 12.50K | — |
| Valentine Keith | Award | 24.83K | — |
| GELLER EHUD | Award | 31.25K | — |
| Alpert Susan PHD MD | Award | 24.83K | — |
Short interest
Settled Sep 30, 2026
- Shares short
- 3.81K
- Days to cover
- 1.00
- % of shares outstanding
- —
- Average daily volume
- 63.91K
- Change since last report
- −42.4%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.